AzTrials
AzTrials

Renal TransplantionPhase 4PRIDENCT00492661

A Pilot Trial to Evaluate the Effect of Diet and Exercise in Renal Transplant Recipients on Tacrolimus

A Phase 4 study testing Tacrolimus With Diet and Exercise Intervention in people with Renal Transplantion and Kidney Transplantion, run by Janssen-Cilag Pty Ltd at 4 sites in Australia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this trial is to investigate whether a combined dietary and exercise intervention, added to standard care, reduces the expected frequency of insulin resistance in renal (kidney) transplant recipients on tacrolimus. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Renal Transplantion, Kidney Transplantion
What is being tested?
Tacrolimus With Diet and Exercise Intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
55 participants
Where
4 sitesAustralia
Study dates
Jul 2007to Jun 2010
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participants who has sufficiently recovered from surgery to tolerate an intensive exercise evaluation
  • Participants who have received a living-donor or cadaveric (from dead donor) renal transplant
  • Participants who has been initiated tacrolimus as first-line immunosuppressive agent
  • Participants who has given informed consent forms

Who cannot join

  • Participants with significant disease or disability that prevents taking part in a diet or exercise regime (e.g. cardiac instability, including unstable angina [chest pain due to decreased oxygen being supplied to the heart] and/or other unstable disease, severe cognitive [mental functioning] impairment)
  • Participants with significant post-surgical complications that prevent participation in the exercise component of the study (e.g. wound dehiscence [pathologic process consisting of a partial or complete disruption of the layers of a surgical wound] or infection)
  • Participants with contraindications to maximal exercise testing or high-intensity progressive resistance training (e.g. proliferative diabetic or hypertensive retinopathy, un-repaired aneurysm, critical aortic stenosis, recurrent symptomatic hernias, New York Heart Association (NYHA) class-IV congestive heart failure)
  • Participants with non-ambulatory (mobility) status
  • Participants who require ongoing systemic immunosuppressive therapy for an indication other than renal transplant and this therapy is higher than that required for their kidney disease

Trial locations and contacts

4 sites in 1 country.

Australia4 sites
  • Study site

    Camperdown

  • Study site

    Clayton

  • Study site

    Perth

  • Study site

    Woodville

Other trials in Australia

About this study

Official title: A Pilot Trial of the Effect of Dietary and Exercise Intervention on Insulin Resistance and Metabolic Parameters in De Novo Renal Transplant Recipients on Prograf (Tacrolimus)

The purpose of this trial is to investigate whether a combined dietary and exercise intervention, added to standard care, reduces the expected frequency of insulin resistance in renal (kidney) transplant recipients on tacrolimus.

Read the detailed description

This is an open-label (all people know the identity of the intervention), prospective (study following participants forward in time), single-arm, multi-center (conducted in more than 1 center), interventional pilot study of the effects of a combined dietary and exercise intervention on glucose metabolism. The duration of this study will be 6 months and will include following visits: Baseline, Week 4, Week 12, and Week 24. Dietary compliance will be evaluated with a 3-day food record and during weekly telephone conversations and face-to-face visits with a dietician. Exercise compliance will be measured using an exercise log presented to the co-ordinator at the end of each month. Primarily, participants with insulin resistance will be assessed by Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) of greater than 1 at 6 months. Participants' safety and tolerability will be monitored throughout the study.

Being tested
Tacrolimus With Diet and Exercise Intervention
Keywords
Tacrolimus, Prograf, PRIDE

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tacrolimus With Diet and Exercise InterventionDrug

    Also called Prograf

    Participants on tacrolimus for immunosuppression will be provided with intensive dietary advice and supervised for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.

Study groups in NCT00492661
Study groupRoleWhat they receive
Tacrolimus With Diet and Exercise InterventionExperimentalParticipants on tacrolimus for immunosuppression (drug which suppresses the body's immune response, used in transplantation and diseases caused by disordered immunity) will be provided with intensive dietary advice and supervised progressive resistance training (PRT) for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
Receives: Drug: Tacrolimus With Diet and Exercise Intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With Insulin Resistance

    Percentage of participants with insulin resistance as defined by a Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) greater than 1. HOMA uses fasting glucose and insulin (or C-peptide) to assess beta-cell function and IR. HOMA-IR is used to estimate insulin resistance. HOMA-IR is calculated by equation: HOMA-IR=fasting plasma insulin (milliunit [mU] per liter [L]) * fasting plasma glucose (millimole per liter [mmol per L]) divided by 22.5.

    Measured: Week 24

Secondary outcomes (18)
  1. Percentage of Participants With Impaired Fasting Glycaemia (IFG)

    IFG is defined as a fasting venous plasma glucose concentration greater than or equal to 6.1 mmol per L but less than 7.0 mmol per L, together with a 2-hour plasma glucose concentration of less than 7.8 mmol per L.

    Measured: Week 24

  2. Percentage of Participants With Impaired Glucose Tolerance (IGT)

    IGT is defined as fasting venous plasma glucose of less than 7.0 mmol per L, together with a 2-hour plasma glucose of greater than or equal to 7.8 mmol per L but less than 11.1 mmol per L.

    Measured: Week 24

  3. Percentage of Participants With Diabetes Mellitus (DM)

    DM is defined as a fasting plasma glucose concentration greater than or equal to 7.0 mmol per L, or a 2-hour plasma glucose greater than or equal to 11.1 mmol per L.

    Measured: Week 24

  4. Beta Cell Function

    HOMA-Beta is used to assess beta-cell function. HOMA-Beta is a measure of Beta-cell function (higher values present increased insulin secretion for a given glucose level). HOMA-Beta is calculated by the equation: HOMA-Beta=(20*FPI) divided by (FPG-3.5), where, FPI is fasting plasma insulin concentration (mU per L) and FPG is fasting plasma glucose concentration (mmol per L).

    Measured: Baseline, Week 4, Week 12, and Week 24

  5. Number of Participants With Acute Rejection, Graft Loss and Death

    Acute rejection episodes are classified into: Spontaneously resolving - a rejection episode which is not treated with new or increased corticosteroid medication, antibodies or any other medication. Corticosteroid sensitive - a rejection episode, which is treated with new or increased corticosteroid medication only. Corticosteroid resistant - a rejection episode, which is not resolve following treatment with corticosteroids. Graft loss is defined as re-transplantation, nephrectomy, death or as dialysis ongoing at study end (or at withdrawal of the participants from the study).

    Measured: Week 24

  6. Body Mass Index (BMI)

    BMI is a statistical measurement which compares a person's weight and height. Though it does not actually measure the percentage of body fat, it is used to estimate a healthy body weight based on participant's height. BMI is equal to weight divided by height square. Weight is measured in Kilogram and height is measured in meter.

    Measured: Baseline, Week 4, Week 12 and Week 24

  7. Bone Mineral Density

    Bone mineral density is measured by Dual-Energy X-ray Absorptiometry (DEXA).

    Measured: Baseline and Week 24

  8. Waist to Hip Ratio (WHR)

    WHR is performed using a standard medical measuring tape, with recordings documented in centimeters. Measurements will be compared against data from participating sites (where available) and against baseline. Measurement of hip circumference will be performed at the widest part of the buttocks. Measurement of the waist will be performed at the smaller circumference of the natural waist (usually just superior to the umbilicus). WHR is calculated by dividing the waist measurement by the hip measurement, and recorded to 2 decimal places.

    Measured: Baseline, Week 4, Week 12 and Week 24

  9. Body Composition: Percent Body Fat

    Body fat will be assessed by DEXA scan.

    Measured: Baseline and Week 24

  10. Body Composition: Lean Mass, Bone Mass and Adjusted Weight

    Body composition lean mass and bone mass will be assessed by DEXA scan.

    Measured: Baseline and Week 24

  11. Body Composition: T Score (Full Body) and Z Score (Full Body)

    Body composition: T score (Full body) and Z score (full body) will be assessed by DEXA scan.

    Measured: Baseline and Week 24

  12. Blood Pressure: Systolic and Diastolic Pressure

    Measurement of blood pressure will be performed by using a completely automated device consisting of an inflatable cuff and oscillatory detection system. Blood pressure will be taken supine, after 5 minutes of rest.

    Measured: Baseline, Week 4, Week 12 and Week 24

  13. Lipid Profile

    In lipid profile total cholesterol, high-density lipoprotein (HDL) - cholesterol, low-density lipoprotein (LDL) - cholesterol and triglycerides levels will be evaluated. Measurement of the lipid profile will be performed in fasted state.

    Measured: Baseline, Week 4, Week 12, and Week 24

  14. Hemoglobin A, Glycosylated (HbA1c)

    Measurement of the change in HbA1c will be performed in fasted state and in local laboratories.

    Measured: Baseline, Week 4, Week 12 and Week 24

  15. Estimated Glomerular Filtration Rate (eGFR)

    The eGFR is calculated by Modification of Diet in Renal Disease (MDRD) equation is recommended by Kidney Health Australia as the calculation of choice for predicting GFR. According to MDRD equation eGFR is equal to 186*(Serum creatinine/0.095)^-1.154*age^0.203*race*sex, where the unit of serum creatinine is micro mole per L, the age is in years; race is 1.212 if African American, or 1 otherwise; and sex equals 1 if male, and 0.742 if female. eGFR will be compared against baseline.

    Measured: Baseline, Week 4, Week 12 and Week 24

  16. 36-Item Short-Form (SF-36) Score - Health Survey

    This SF-36 standardize survey evaluates participants health by 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as Physical Component Scores (PCS) and Mental Component Scores (MCS). The score for a section is an average of the individual question scores, which are scaled 0 to 100, Higher score indicates highest level of functioning.

    Measured: Baseline, Week 12 and Week 24

  17. Percentage of Participants who will be Sedentary, Insufficiently Active and Sufficiently Active According to Active Australia Survey (AAS)

    AAS is used for physical activity surveillance and it consists of following categories: 'sedentary' - people who are doing no activity at all; 'sufficiently active'- participation in at least 150 minutes per week; 'insufficiently active'- the remainder participants whose participation is not enough to obtain a health benefit.

    Measured: Week 4, Week 12 and Week 24

  18. Percentage of Participants Compliant With Both Dietary Advice and Exercise Program and Non-Compliant With Dietary Advice or Exercise Program

    Compliance with dietary advice will be measured on a categorical scale ranging from 0=no compliance to 10=full compliance. Compliance with exercise program is measured as the completion of 3 exercise sessions per week for the 6-month period.

    Measured: Week 4, Week 12 and Week 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jun 2007 (estimated)
  2. Study startJul 2007
  3. Primary completionJun 2010
  4. Study completionJun 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
55 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00492661
Sponsor's protocol ID
CR013702
Other IDs
OTH/506TRA4004
Acronym
PRIDE
Status last verified
May 2013
First submitted
25 Jun 2007
Last updated
27 May 2013
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Tacrolimus With Diet and Exercise Intervention in people with Renal Transplantion and Kidney Transplantion, run by Janssen-Cilag Pty Ltd at 4 sites in Australia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 May 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With Insulin Resistance (time frame: Week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 May 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in